TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22817833

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 789

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 789
Study: 21189203

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine via a popliteal catheter for 72 hours
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline via a popliteal catheter for 72 hours (Control)
Number of subjects: 54
Study: 18179318

Group type: EXPERIMENTAL
Intervention: Internal motivation for nonprejudiced responses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of internal and external motivation for nonprejudiced responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conflict monitoring activity measured by event-related potentials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response control in the domain of prejudice
Number of subjects: 0
Study: 15712768

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo therapeutic touch
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 12670812

Group type: EXPERIMENTAL
Intervention: Intrathecal + PCA morphine (IT+PCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 10767356

Group type: EXPERIMENTAL
Intervention: Oral doxifluridine (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 5-fluorouracil (group B)
Number of subjects: 150
Study: 9310220

Group type: EXPERIMENTAL
Intervention: r-hIFN-beta-1a (1 million IU, intralesional, 3 times a week for 9 occasions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (intralesional, 3 times a week for 9 occasions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: r-hIFN-beta-1a
Number of subjects: 60
Study: 8422744

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (250 mg) and Ethinyl Estradiol (50 micrograms)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Desogestrel (150 micrograms) and Ethinyl Estradiol (30 micrograms)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1055
Study: 2947150

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg per tablet, 3 tablets daily for one month)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31399480

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Paper guidance
Number of subjects: 2
Study: 29459121

Group type: EXPERIMENTAL
Intervention: Exercise and manual therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercise and manual therapy + IFC
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercise and manual therapy + placebo ultrasound
Number of subjects: 45
Study: 26884473

Group type: EXPERIMENTAL
Intervention: Long-acting (pegylated) C-peptide 0.8 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Long-acting (pegylated) C-peptide 2.4 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combined C-peptide groups
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: C-peptide therapy
Number of subjects: 250
Study: 24753534

Group type: EXPERIMENTAL
Intervention: ≥2 anxiety comorbidities (n = 143; 39%)
Number of subjects: 392

Group type: COMPARATOR
Intervention: No anxiety comorbidities (n = 132; 36%)
Number of subjects: 392

Group type: COMPARATOR
Intervention: 1 anxiety comorbidity (n = 95; 26%)
Number of subjects: 392
Study: 23718253

Group type: EXPERIMENTAL
Intervention: Vitamins C and E
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study: 20347616

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study: 18391603

Group type: EXPERIMENTAL
Intervention: LMI alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide followed by LMI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide followed by LMI with IL-2
Number of subjects: 61
Study: 16466758

Group type: EXPERIMENTAL
Intervention: Equine F(ab')2 antivenom
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14725391

Group type: EXPERIMENTAL
Intervention: Life review and reminiscence therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional forms of counselling and psychotherapy
Number of subjects: 0
Study: 10944641

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 microg/kg twice per day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 microg/kg twice per day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 microg/kg twice per day
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 8998919

Group type: EXPERIMENTAL
Intervention: 23-valent vaccine of capsular polysaccharides (Pneumovax 23)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (23 subjects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 31
Study: 30376884

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg every 12 hours for 4 days (first dose prior to kidney transplantation)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 132
Study: 27070853

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention for Social Anxiety Disorder (MBI-SAD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 21
Study: 26576424

Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) + Remifentanil (0.05 μg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) + Fentanyl (1 μg/kg)
Number of subjects: 90
Study: 23995984

Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy (Hb 8.0 g/dl)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Liberal RBC transfusion strategy (Hb 10.8 g/dl)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Liberal RBC transfusion strategy
Number of subjects: 107
Study: 20655177

Group type: EXPERIMENTAL
Intervention: Dento‐alveolar distraction
Number of subjects: 6

Group type: COMPARATOR
Intervention: Periodontal distraction
Number of subjects: 6
Study: 18830037

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study: 16439935

Group type: EXPERIMENTAL
Intervention: Dérinox (D)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Rhinofluimucil (R)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 354
Study: 11875365

Group type: EXPERIMENTAL
Intervention: Tolbutamide (500 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10359022

Group type: EXPERIMENTAL
Intervention: LCP1 formula (0.31% 18:3 omega6, 0.17% 20:5 omega3, 0.20% 22:6 omega3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LCP2 formula (0.32% 18:3 omega6, 0.34% 20:5 omega3, 0.43% 22:6 omega3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary 20:5 omega3 and 22:6 omega3
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary 20:5 omega3 and LCPUFA omega3
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LCP1 and LCP2 fed infants
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Added 18:3 omega6
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 47
Study: 7735582

Group type: EXPERIMENTAL
Intervention: Modipafant (50 mg capsule twice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 120
Study: 1688330

Group type: EXPERIMENTAL
Intervention: Oxatomide gel 5% (2 applications a day for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (2 applications a day for 7 days)
Number of subjects: 20
Study: 6794584

Group type: EXPERIMENTAL
Intervention: Lysine acetyl salicylate (LAS) 1.8 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 0
Study: 30646890

Group type: EXPERIMENTAL
Intervention: Dental caries experience
Number of subjects: 90
Study: 28141630

Group type: EXPERIMENTAL
Intervention: Modified Electroconvulsive Therapy (MECT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atypical antipsychotic treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (Healthy controls)
Number of subjects: 100
Study: 26510464

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 80 ppm by non-rebreather mask
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (room air)
Number of subjects: 180
Study: 23340761

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Classic incision
Number of subjects: 90

Group type: COMPARATOR
Intervention: Short incision
Number of subjects: 90
Study: 19950112

Group type: EXPERIMENTAL
Intervention: Body checking
Number of subjects: 66

Group type: COMPARATOR
Intervention: Body exposure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study: 19254629

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 57
Study: 17397061

Group type: EXPERIMENTAL
Intervention: Active treatment (10-week functional continuous magnetic stimulation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham treatment (initial 10-week sham treatment)
Number of subjects: 39
Study: 15061748

Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 84
Study: 11282809

Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 57

Group type: COMPARATOR
Intervention: Dim red light
Number of subjects: 57
Study: 19160722

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg o.d.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg o.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8387912

Group type: EXPERIMENTAL
Intervention: Isabgol husk (25 g) added to low-fibre diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fibre diet (control)
Number of subjects: 11
Study: 3111669

Group type: EXPERIMENTAL
Intervention: 30 mg sodium fluoride (NaF) + 1 g calcium
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10 mg sodium fluoride (NaF) + calcium
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 26305570

Group type: EXPERIMENTAL
Intervention: Transfusion (Tx)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 80
Study: 24281460

Group type: EXPERIMENTAL
Intervention: Multivitamins plus selenium
Number of subjects: 878

Group type: COMPARATOR
Intervention: Multivitamins alone
Number of subjects: 878

Group type: COMPARATOR
Intervention: Selenium alone
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study: 21054362

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study: 18494811

Group type: EXPERIMENTAL
Intervention: Twice-daily 50/50 premixed insulin lispro (Mix50 group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Basal-bolus (BB) therapy (NPH insulin at bedtime and preprandial insulin lispro)
Number of subjects: 28
Study: 16541853

Group type: EXPERIMENTAL
Intervention: Reducing south and reinforcing north needling method
Number of subjects: 90

Group type: COMPARATOR
Intervention: Capoten and aspirin
Number of subjects: 90
Study: 12437644

Group type: EXPERIMENTAL
Intervention: High sCD62L levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low sCD62L levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Normal sCD62L levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low, normal, and high sCD62L levels in non-S3/S4 patients
Number of subjects: 193
Study: 10326217

Group type: EXPERIMENTAL
Intervention: Weekly L-asparaginase (l-Asp) during maintenance therapy as a late intensification
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard maintenance therapy without additional L-asparaginase (l-Asp)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Full dose of daunorubicin (DNR, 450 mg/m2 in total)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol AL841
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Complete remission (CR) achieved with three-drug induction
Number of subjects: 62
Study: 7472590

Group type: EXPERIMENTAL
Intervention: Tetrofosmin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sestamibi
Number of subjects: 30
Study: 1937073

Group type: EXPERIMENTAL
Intervention: Argon-laser trabeculoplasty (performed on one eye)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (fellow eye, no treatment)
Number of subjects: 25
Study: 6811177

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31124409

Group type: EXPERIMENTAL
Intervention: Drug treatment involving COMT modulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31210343

Group type: EXPERIMENTAL
Intervention: Saudi nutrition policy compliance
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Institute of Medicine (IOM) standards compliance
Number of subjects: 76
Study: 28156185

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Monomethyl fumarate (MMF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 24698135

Group type: EXPERIMENTAL
Intervention: ACT DVD + 12-week pedometer-based walking programme
Number of subjects: 59

Group type: COMPARATOR
Intervention: Walking programme in isolation
Number of subjects: 59
Study: 24379032

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21793958

Group type: EXPERIMENTAL
Intervention: Incentive group (contingency management)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 319
Study: 19907854

Group type: EXPERIMENTAL
Intervention: METAPEX
Number of subjects: 178

Group type: COMPARATOR
Intervention: Zinc oxide eugenol paste (control)
Number of subjects: 178
Study: 17076067

Group type: EXPERIMENTAL
Intervention: Circle (small and large; no part structure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bell (shape with two parts, one larger than the other)
Number of subjects: 0
Study: 15347035

Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg/day during 10 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nifedipine (45 mg/day during 10 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (for 10 days)
Number of subjects: 43
Study: 11320583

Group type: EXPERIMENTAL
Intervention: Videolaryngostroboscope
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Measurements of vibration, amplitude, frequency and mucosal wave of vocal cords
Number of subjects: 99
Study: 9146782

Group type: EXPERIMENTAL
Intervention: Capsules with enteric-coated microtablets (2 capsules, 40,000 U lipase and 2000 proteases)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enteric-coated tablets (3 tablets, 40,000 U lipase and 2000 proteases)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no enzymes, n = 20)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no enzymes)
Number of subjects: 20
Study: 7970446

Group type: EXPERIMENTAL
Intervention: Toshiba GCA-9300A SPET system with lead fanbeam super high-resolution collimators (SHR FB) for 99Tcm-HMPAO brain SPET studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toshiba GCA-9300A SPET system with high-resolution parallel-hole collimators (HR PH) for cardiac and other body studies
Number of subjects: 0
Study: 2890021

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31900080

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU fortnightly) + Calcium (500 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU fortnightly) + Calcium placebo
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (Vitamin D and Calcium)
Number of subjects: 81
Study: 28918652

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 37

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 37
Study: 27225739

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam (Group L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol (Group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 60
Study: 24458173

Group type: EXPERIMENTAL
Intervention: Red ginseng anti-hangover drink (RGD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (100 mL water)
Number of subjects: 25
Study: 23782587

Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin twice daily co-administered with 0.2 mg voglibose three times daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 mg vildagliptin twice daily
Number of subjects: 24
Study: 21083918

Group type: EXPERIMENTAL
Intervention: bio-psycho-social chronic back pain specific aftercare intervention (RÜCKGEWINN)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: usual aftercare (IRENA)
Number of subjects: 456

Group type: COMPARATOR
Intervention: educational booklet addressing pain-conditioned functional ability and back pain episodes
Number of subjects: 456
Study: 18230277

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (MUFA) enteral formula
Number of subjects: 22

Group type: COMPARATOR
Intervention: High-carbohydrate enteral formula
Number of subjects: 22
Study: 16767422

Group type: EXPERIMENTAL
Intervention: Tryptophan (1 g 3x a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 14531252

Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetracaine 10 mg
Number of subjects: 0
Study: 10979796

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 9002808

Group type: EXPERIMENTAL
Intervention: Fuji Cap II
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: APH/Universal Bond 3
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lite Fil II A/Imperva Bond
Number of subjects: 83
Study: 1480768

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) of 80.5 Gy in 70 fractions in 7 weeks using 2 fractions of 1.15 Gy per day
Number of subjects: 356

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) of 70 Gy in 35-40 fractions in 7-8 weeks
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Both HF and CF
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF)
Number of subjects: 356
Study: 453496

Group type: EXPERIMENTAL
Intervention: Etomidate (0.25 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etomidate (intravenous injection)
Number of subjects: 50
Study: 31162585

Group type: EXPERIMENTAL
Intervention: HAW breads (high-amylose wheat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LAW breads (low-amylose wheat)
Number of subjects: 20
Study: 28735463

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 42
Study: 26480555

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Auricular point
Number of subjects: 90
Study: 23921780

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling (BLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling (EBLC)
Number of subjects: 0
Study: 22153012

Group type: EXPERIMENTAL
Intervention: Xingnaojing (20 ml/d i.v. drip) + L-carnitine (2 g/d i.v. drip)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Xingnaojing (20 ml/d i.v. drip)
Number of subjects: 69
Study: 19826292

Group type: EXPERIMENTAL
Intervention: Sublingual ergogenic spray containing vitamins, minerals, amino acids, and a coenzyme
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17101639

Group type: EXPERIMENTAL
Intervention: Pharmacy care program (standardized medication education, regular follow-up by pharmacists, medications dispensed in time-specific packs)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pharmacy care program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pharmacy care
Number of subjects: 200
Study: 16169367

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (240 ml/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo beverage (similar caloric content, amount, flavor, and color)
Number of subjects: 45
Study: 12945828

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g creatine monohydrate for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10085546

Group type: EXPERIMENTAL
Intervention: Two-model problem with the crucial premise in the last position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-model problem with the crucial premise in the first position
Number of subjects: 0
Study: 7891248

Group type: EXPERIMENTAL
Intervention: Conventional manual probe
Number of subjects: 15

Group type: COMPARATOR
Intervention: Automated force-controlled electronic probe
Number of subjects: 15
Study: 2236581

Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg administered orally in divided doses for 12 weeks
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178